The biotech is eyeing a 2027 start for divesiran's Phase III trial as it plays catch-up to Takeda and Protagonist's rusfertide.
The biotech is eyeing a 2027 start for divesiran's Phase III trial as it plays catch-up to Takeda and Protagonist's rusfertide.